It is our mandate to catalyse and facilitate growth in the cell and gene therapy industry. Since our inception in 2012, we have been gathering qualitative and quantitative data to showcase the impact we are having on the companies and researchers we work with and on general industry growth.
UK companies have received
£1.3bn+investment
There are
64
ATMP developers in the UK compared to 22 in 2012
There has been
190%
growth in the number of ATMP developers
There are
59
active clinical trials in 2017, compared to 21 in 2012
There has been
180%
growth in UK clinical trials
There are
+1,000
jobs compared to 540 in 2012
There are
22
GMP facilities compared to 11 in 2012
There has been
100%
increase in the number of GMP manufacturing facilities
The
>7,000m2
CGT Catapult manufacturing centre is opening in 2017
